Hurdles Toward a Cure for CML: The CML Stem Cell

Hematology/Oncology Clinics of North America

Volumn 25, Issue 5, 2011, Pages 951-966

  Gallipoli, Paolo ^a   Abraham, Sheela A ^a,b   Holyoake, Tessa L ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Chronic myeloid leukemia; Cure; Stem cell; Targeted therapy

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BORTEZOMIB; ERISMODEGIB; FINGOLIMOD; HYDROXYCHLOROQUINE; IMATINIB; LONAFARNIB; LY 364947; PANOBINOSTAT; UNCLASSIFIED DRUG;

CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL DIFFERENTIATION; CELL EXPANSION; CELL RENEWAL; CELL SUBPOPULATION; CHRONIC MYELOID LEUKEMIA; DRUG WITHDRAWAL; HEMATOPOIETIC STEM CELL; HUMAN; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

DISEASE-FREE SURVIVAL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASTIC STEM CELLS; PROTEIN KINASE INHIBITORS; SURVIVAL RATE;

EID: 80755125628     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2011.09.001     Document Type: Review

References (95)

1. Sawyers C.L. Chronic myeloid leukemia. N Engl J Med 1999, 340(17):1330-1340.
2. Druker B.J., Guilhot F., O'Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355(23):2408-2417.
3. Noens L., van Lierde M.A., De Bock R., et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009, 113(22):5401-5411.
4. Marin D., Bazeos A., Mahon F.X., et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010, 28(14):2381-2388.
5. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005, 5(3):172-183.
6. Michor F., Hughes T.P., Iwasa Y., et al. Dynamics of chronic myeloid leukaemia. Nature 2005, 435(7046):1267-1270.
7. Roeder I., Glauche I. Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia-insights from mathematical model analyses. J Mol Med 2008, 86(1):17-27.
8. Dick J.E. Stem cell concepts renew cancer research. Blood 2008, 112(13):4793-4807.
9. Becker A.J., McCulloch E.A., Till J.E. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature 1963, 197:452-454.
10. Nowell P.C. The clonal evolution of tumor cell populations. Science 1976, 194(4260):23-28.
11. Lapidot T., Sirard C., Vormoor J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367(6464):645-648.
12. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3(7):730-737.
13. Clarke M.F., Dick J.E., Dirks P.B., et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006, 66(19):9339-9344.
14. Misaghian N., Ligresti G., Steelman L.S., et al. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia 2009, 23(1):25-42.
15. Lane S.W., Scadden D.T., Gilliland D.G. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 2009, 114(6):1150-1157.
16. Schatton T., Frank N.Y., Frank M.H. Identification and targeting of cancer stem cells. Bioessays 2009, 31(10):1038-1049.
17. Frank N.Y., Schatton T., Frank M.H. The therapeutic promise of the cancer stem cell concept. J Clin Invest 2010, 120(1):41-50.
18. Hong D., Gupta R., Ancliff P., et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 2008, 319(5861):336-339.
19. Quintana E., Shackleton M., Sabel M.S., et al. Efficient tumour formation by single human melanoma cells. Nature 2008, 456(7222):593-598.
20. Shackleton M., Quintana E., Fearon E.R., et al. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009, 138(5):822-829.
21. Dick J.E. Looking ahead in cancer stem cell research. Nat Biotechnol 2009, 27(1):44-46.
22. Jaksch M., Munera J., Bajpai R., et al. Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines. Cancer Res 2008, 68(19):7882-7886.
23. Kelly P.N., Dakic A., Adams J.M., et al. Tumor growth need not be driven by rare cancer stem cells. Science 2007, 317(5836):337.
24. Kennedy J.A., Barabe F., Poeppl A.G., et al. Comment on "Tumor growth need not be driven by rare cancer stem cells" Science 2007, 318(5857):1722. [author reply: 1722].
25. Schatton T., Murphy G.F., Frank N.Y., et al. Identification of cells initiating human melanomas. Nature 2008, 451(7176):345-349.
26. Cortes J.E., Jones D., O'Brien S., et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010, 28(3):392-397.
27. Cortes J.E., Jones D., O'Brien S., et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010, 28(3):398-404.
28. Holyoake T., Jiang X., Eaves C., et al. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999, 94(6):2056-2064.
29. Jorgensen H.G., Allan E.K., Jordanides N.E., et al. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 2007, 109(9):4016-4019.
30. Copland M., Hamilton A., Elrick L.J., et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006, 107(11):4532-4539.
31. Graham S.M., Jorgensen H.G., Allan E., et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002, 99(1):319-325.
32. Konig H., Holtz M., Modi H., et al. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia 2008, 22(4):748-755.
33. Konig H., Holyoake T.L., Bhatia R. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood 2008, 111(4):2329-2338.
34. Chu S., Lin A., McDonald T., et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib treatment for 5 years. Blood 2008, 112(11):79.
35. Mahon F., Rea F., Guilhot F., et al. Discontinuation of imatinib therapy after achieving a molecular response in chronic myeloid leukemia patients. Blood 2009, 114(22). [abstract: 859].
36. Weinstein I.B., Joe A. Oncogene addiction. Cancer Res 2008, 68(9):3077-3080. [discussion: 3080].
37. Hughes T., Saglio G., Martinelli G., et al. Responses and disease progression in CML-CP patients treated with nilotinib after imatinib failure appear to be affected by the BCR-ABL mutation status and types. Blood 2007, 110(11):101a.
38. Jiang X., Zhao Y., Smith C., et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007, 21(5):926-935.
39. Mahon F.X., Belloc F., Lagarde V., et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003, 101(6):2368-2373.
40. Engler J.R., Frede A., Saunders V.A., et al. Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. Leukemia 2010, 24(4):765-770.
41. Jordanides N.E., Jorgensen H.G., Holyoake T.L., et al. Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 2006, 108(4):1370-1373.
42. Houghton P.J., Germain G.S., Harwood F.C., et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 2004, 64(7):2333-2337.
43. Burger H., van Tol H., Boersma A.W., et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 2004, 104(9):2940-2942.
44. Hatziieremia S., Jordanides N.E., Holyoake T.L., et al. Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib. Exp Hematol 2009, 37(6):692-700.
45. White D.L., Saunders V.A., Dang P., et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007, 110(12):4064-4072.
46. Davies A., Jordanides N.E., Giannoudis A., et al. Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia 2009, 23(11):1999-2006.
47. Zhang X., Ren R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 1998, 92(10):3829-3840.
48. Gross A.W., Zhang X., Ren R. Bcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy. Mol Cell Biol 1999, 19(10):6918-6928.
49. Johnson K.J., Griswold I.J., O'Hare T., et al. A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice. PLoS One 2009, 4(10):e7439.
50. Huntly B.J., Shigematsu H., Deguchi K., et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 2004, 6(6):587-596.
51. Schemionek M., Elling C., Steidl U., et al. BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood 2010, 115(16):3185-3195.
52. Sharma S.V., Fischbach M.A., Haber D.A., et al. "Oncogenic shock": explaining oncogene addiction through differential signal attenuation. Clin Cancer Res 2006, 12(14 Pt 2):4392s-4395s.
53. Sharma S.V., Gajowniczek P., Way I.P., et al. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 2006, 10(5):425-435.
54. Hu Y., Swerdlow S., Duffy T.M., et al. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci U S A 2006, 103(45):16870-16875.
55. Donato N.J., Wu J.Y., Stapley J., et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004, 64(2):672-677.
56. Zhao C., Chen A., Jamieson C.H., et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009, 458(7239):776-779.
57. Dierks C., Beigi R., Guo G.R., et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 2008, 14(3):238-249.
58. Irvine D., Zhang B., Allan E., et al. Combination of the hedgehog pathway inhibitor LDE225 and nilotinib eliminates chronic myeloid leukemia stem and progenitor cells. Blood 2009, 114(22). [abstract: 1428].
59. Nusse R. Wnt signaling and stem cell control. Cell Res 2008, 18(5):523-527.
60. Hu Y., Chen Y., Douglas L., et al. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia 2009, 23(1):109-116.
61. Peterson L., Turbiak A., Giannola D., et al. Wnt-pathway directed compound targets blast crisis and chronic phase CML leukemia stem progenitors. Blood 2009, 114(22). [abstract: 2168].
62. Neviani P., Santhanam R., Trotta R., et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005, 8(5):355-368.
63. Neviani P., Santhanam R., Ma Y., et al. Activation of PP2A by FTY720 inhibits survival and self-renewal of the Ph(+) chronic myelogenous leukemia (CML) CD34+/CD38- stem cell through the simultaneous suppression of BCR/ABL and BCR/ABL- independent signals. Blood 2008, 112(11). [abstract: 189].
64. Naka K., Hoshii T., Muraguchi T., et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010, 463(7281):676-680.
65. Pellicano F, Huntly BJ, Holyoake TL. Investigation of the role of FOXO in TKI-induced G1 arrest as potential targets in CML stem/progenitor cell eradication. Abstract presented at ESH-EHA Scientific Workshop Leukemic and Cancer Stem Cells. Mandelieu (France), April 3-5, 2009.
66. Jorgensen H.G., Copland M., Allan E.K., et al. Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clin Cancer Res 2006, 12(2):626-633.
67. Holtz M., Forman S.J., Bhatia R. Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment. Cancer Res 2007, 67(3):1113-1120.
68. Drummond M.W., Heaney N., Kaeda J., et al. A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response. Leukemia 2009, 23(6):1199-1201.
69. Salomoni P., Pandolfi P.P. The role of PML in tumor suppression. Cell 2002, 108(2):165-170.
70. Ito K., Bernardi R., Morotti A., et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008, 453(7198):1072-1078.
71. Borthakur G., Kantarjian H., Daley G., et al. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer 2006, 106(2):346-352.
72. Jorgensen H.G., Allan E.K., Graham S.M., et al. Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia 2005, 19(7):1184-1191.
73. Copland D.A., Wertheim M.S., Armitage W.J., et al. The clinical time-course of experimental autoimmune uveoretinitis using topical endoscopic fundal imaging with histologic and cellular infiltrate correlation. Invest Ophthalmol Vis Sci 2008, 49(12):5458-5465.
74. Pellicano F., Copland M., Jorgensen H.G., et al. BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cbeta. Blood 2009, 114(19):4186-4196.
75. Jiang X., Lopez A., Holyoake T., et al. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci U S A 1999, 96(22):12804-12809.
76. Hiwase D.K., White D.L., Powell J.A., et al. Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors. Leukemia 2010, 24(4):771-778.
77. Wang Y., Cai D., Brendel C., et al. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood 2007, 109(5):2147-2155.
78. Samanta A., Chakraborty S., Sun X., et al. Jak2 phosphorylates Tyr 177 of Bcr-Abl activating the Ras and PI-3 kinase pathways and maintains functional levels of Bcr-Abl in chronic myelogenous leukemia. Blood 2009, 114(22). [abstract: 39].
79. Mercurio C., Minucci S., Pelicci P.G. Histone deacetylases and epigenetic therapies of hematological malignancies. Pharm Res 2010, 62(1):18-34.
80. Zhang B., Campbell Strauss A., Chu S., et al. Effective targeting of quiescent CML stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Blood 2009, 114(22). [abstract: 190].
81. Bhatia R., Snyder D., Lin A., et al. A phase I study of the HDAC inhibitor LBH589 in combination with imatinib for patients with CML in cytogenetic remission with residual disease detectable by Q-PCR. Blood 2009, 114(22). [abstract: 2194].
82. Heaney N.B., Pellicano F., Zhang B., et al. Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. Blood 2010, 115(11):2241-2250.
83. Klionsky D.J. Autophagy: from phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol 2007, 8(11):931-937.
84. Lum J.J., Bauer D.E., Kong M., et al. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 2005, 120(2):237-248.
85. Bellodi C., Lidonnici M.R., Hamilton A., et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009, 119(5):1109-1123.
86. Kolb H.J., Schattenberg A., Goldman J.M., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995, 86(5):2041-2050.
87. Kolb H.J., Mittermuller J., Clemm C., et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990, 76(12):2462-2465.
88. Rojas J.M., Knight K., Wang L., et al. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia 2007, 21(11):2287-2295.
89. Jain N., Reuben J.M., Kantarjian H., et al. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer 2009, 115(17):3924-3934.
90. Smith B.D., Kasamon Y.L., Kowalski J., et al. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res 2010, 16(1):338-347.
91. Maslak P.G., Dao T., Gomez M., et al. A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease. Leukemia 2008, 22(8):1613-1616.
92. Li Z., Qiao Y., Liu B., et al. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin Cancer Res 2005, 11(12):4460-4468.
93. Kantarjian H.M., O'Brien S., Cortes J.E., et al. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003, 97(4):1033-1041.
94. Molldrem J.J., Lee P.P., Wang C., et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000, 6(9):1018-1023.
95. Burchert A., Muller M.C., Kostrewa P., et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 2010, 28(8):1429-1435.